Kjzic9lxra20u7hrjjc8 definiens vector cmyk rev 250x60px

Definiens, Inc.

ic No Reviews Yet
ic No Completed Orders
Cambridge, Massachusetts, US

About Definiens, Inc.

We improve patient lives by unlocking the tissue phenome

In oncology, therapeutic strategies have shifted from a direct assault on cancer cells to recruiting the immune system for that purpose. Our mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to... Show more »

We improve patient lives by unlocking the tissue phenome

In oncology, therapeutic strategies have shifted from a direct assault on cancer cells to recruiting the immune system for that purpose. Our mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, to bring multi-omics data into a cancer-relevant context, and to facilitate the translation of new insights into novel therapies and treatment strategies. Our vision is to create unique patient profiles for an individualized standard of care, where patients experience fewer side effects and live longer.

Taking a ground-breaking technology that dramatically improves the information that can be extracted from histological images, Nobel Laureate Dr. Gerd Binnig founded Definiens in 1994. The goal? To create new opportunities for discovery and advances in oncology and immuno-oncology. Since then, Definiens technology has been used in thousands of projects, yielding results that have accelerated drug development and produced over 650 peer-reviewed publications. In 2013, Frost and Sullivan recognized Definiens as Company of the Year for Global Tissue Diagnostics and Pathology Imaging.

Definiens is now an international company with over 100 employees worldwide, and headquartered in Munich, Germany and Cambridge, USA.

Recent Publications

  • E. D. Hawkins, D. Duarte, O. Akinduro, R. A. Khorshed, D. Passaro, M. Nowicka, L. Straszkowski, M. K. Scott, S. Rothery, N. Ruivo, K. Foster, M. Waibel, R. W. Johnstone, S. J. Harrison, D. A. Westerman, H. Quach, J. Gribben, M. D. Robinson, L. E. Purton, D. Bonnet, C. L. Celso. T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. Nature Oct 2016, DOI:10.1038/nature19801
  • K. Showler, M. Nishimura, K. Daino, T. Imaoka, Y. Nishimura, T. Morioka, B. J. Blyth, T. Kokubo, M. Takabatake, M. Fukuda, H. Moriyama, S. Kakinuma, M. Fukushi, Y. Shimada. Analysis of genes involved in the PI3K/Akt pathway in radiation- and MNU-induced rat mammary carcinomas. Journal of Radiation Research Oct 2016, DOI: 10.1093/jrr/rrw097
  • V. Sigl, K. Owusu-Boaitey, P. A. Joshi, A. Kavirayani, G. Wirnsberger, M. Novatchkova, I. Kozieradzki, D. Schramek, N. Edokobi, J. Hersl, A. Sampson, A. Odai-Afotey, C. Lazaro, E. Gonzalez-Suarez, M. A. Pujana, for CIMBA, H. Heyn, E. Vidal, J. Cruickshank, H. Berman, R. Sarao, M. Ticevic, I. Uribesalgo, L. Tortola, S. Rao, Y. Tan, G. Pfeiler, E. YHP Lee, Z. Bago-Horvath, L. Kenner, H. Popper, Ch. Singer, R. Khokha, L. P. Jones, J. M. Penninger. RANKL/RANK control Brca1 mutation-driven mammary tumors. Cell Research Oct 2016, DOI:10.1038/cr.2016.69
  • L. Hammoud, J. R. Adams, A. J. Loch, R. C. Marcellus, D. E. Uehling, A. Aman, Ch. Fladd, T. D. McKee, Ch. E.B. Jo, R. Al-Awar, S. E. Egan, J. Rossant. Identification of RSK and TTK as Modulators of Blood Vessel Morphogenesis Using an Embryonic Stem Cell-Based Vascular Differentiation Assay Stem Cell Reports Oct 2016, DOI: 10.1016/j.stemcr.2016.08.004
  • T. P. Ahern, A. H. Beck, B. A. Rosner, B. Glass, G. Frieling, L. C. Collins, R. M. Tamimi. Continuous measurement of breast tumour hormone receptor expression: a comparison of two computational pathology platforms. Journal of Clinical Pathology Oct 2016, DOI:10.1136/jclinpath-2016-204107
Show less

Our Services (17)


ic

Clinical Biomarkers

Price on request
Request a quote for more information about this service.

ic

Clinical Trial Management

Price on request

Customized analysis of cell status, cell-to-cell dynamics and tissue context of biomarkers unlocks a deeper understanding of cancer. We quantify these features during assay development and the resulting insights drive confident pipeline decisions for clinical trials. Our scientific, regulatory and medical team support you... Show more »

Customized analysis of cell status, cell-to-cell dynamics and tissue context of biomarkers unlocks a deeper understanding of cancer. We quantify these features during assay development and the resulting insights drive confident pipeline decisions for clinical trials. Our scientific, regulatory and medical team support you throughout the process. Our services include:

- Biomarker screening to identify the indication of most impact
- Evaluation of drug response profiles for pharmacodynamics studies
- Exploratory studies with custom assays and quantitative readouts to support regulatory filing

Show less

ic

Biomarker Discovery

Price on request

Assessing the potential of a biomarker to identify patient populations requires correlating patient data with drug responses. Using Tissue Phenomics, we mine data from your tissue samples to find meaningful signatures that link ‘omics data with clinical outcomes and generate insights beyond the scope of other approaches. We... Show more »

Assessing the potential of a biomarker to identify patient populations requires correlating patient data with drug responses. Using Tissue Phenomics, we mine data from your tissue samples to find meaningful signatures that link ‘omics data with clinical outcomes and generate insights beyond the scope of other approaches. We offer:

- Data-rich biomarker readouts from histological slides of any tissue
- Development and evaluation of the most impactful signature candidates
- Unique mining of tissue, ‘omics, outcomes, medical history and other data

Show less

ic

Companion Diagnostic Development

Price on request

Certainty is the hallmark of next-generation diagnostics. Our precise quantitative biomarker readouts and best-in-class assay development in accordance with our certified quality management system, build certainty into your CDx. Our scientific and regulatory teams help design the best strategy to advance your prototype to... Show more »

Certainty is the hallmark of next-generation diagnostics. Our precise quantitative biomarker readouts and best-in-class assay development in accordance with our certified quality management system, build certainty into your CDx. Our scientific and regulatory teams help design the best strategy to advance your prototype to regulatory filing and into the clinic. We support you with:

  • Scientific expertise from board-certified pathologists and top experts in Tissue Phenomics
  • International regulatory knowledge for documentation and interactions with authorities
  • Agile project management in strategy planning and troubleshooting
Show less

ic

Image Analysis

Price on request
Request a quote for more information about this service.

ic

Clinical Data Collection, Analysis and Management

Price on request
Request a quote for more information about this service.

ic

Computational Modeling

Price on request
Request a quote for more information about this service.

ic

Clinical Chemistry

Price on request
Request a quote for more information about this service.

ic

Bioanalysis

Price on request
Request a quote for more information about this service.

ic

Medical Devices & Diagnostics

Price on request
Request a quote for more information about this service.

ic

Data Services

Price on request
Request a quote for more information about this service.

ic

Pharmacology & Toxicology

Price on request
Request a quote for more information about this service.

ic

Clinical Laboratory Services

Price on request
Request a quote for more information about this service.

ic

Antibody/Antigen Detection Based Testing

Price on request
Request a quote for more information about this service.

ic

Biomarkers

Price on request
Request a quote for more information about this service.

ic

Clinical Trials, Consulting, and Management

Price on request
Request a quote for more information about this service.

ic

Clinical Research

Price on request
Request a quote for more information about this service.

Not finding what you're looking for?

Get info on this provider's capabilities without requesting a quote.
Missing Avatar

Benjamin Withey

Director of Business Development
FileType/PDF Created with Sketch.

Assay_Development_to_Stratify_Patients.pdf

FileType/PDF Created with Sketch.

Automated_Scoring_in_Diagnostics.pdf

FileType/PDF Created with Sketch.

Immunoscore_in_Colorectal_Cancer.pdf

FileType/PDF Created with Sketch.

Inflammatory_Tumor_Microenvironment.pdf

FileType/PDF Created with Sketch.

More_Accurate_Scoring_System_for_Patient_Stratification.pdf

FileType/PDF Created with Sketch.

Morphological_Features_Associated_with_Survival.pdf

FileType/PDF Created with Sketch.

Novel_Signature_to_Improve_Patient_Stratification.pdf

Definiens, Inc. has not received any reviews.

Definiens, Inc. has not received any endorsements.